Louise Bracken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louise Bracken has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Peak
Paediatric Medicines Research Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool L12 2AP, UK
9 shared publications - Andrea Gill
Paediatric Medicines Research Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
7 shared publications - Cecile Ayako Dreiss
Institute of Pharmaceutical Science King's College London London UK
5 shared publications - Jennifer Claire Duncan
Neonatal and Paediatric Pharmacy Group London UK
4 shared publications Mohamed A. Alhnan
4 shared publicationsAbdullah Isreb
3 shared publications
Latest Publications
- 20 September 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 704
One ink for two processes: Exploiting rheology to accelerate 3D-printed chewable tablet manufacturing
- 20 September 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 704
One ink for two processes: Exploiting rheology to accelerate 3D-printed chewable tablet manufacturing
- Open Access
- 9 September 2026
- Published by Wiley in Child: Care, Health and Development
- Vol. 52 (5) , e70334
Parent Partnership in Neonatal Research: Facilitators, Barriers and Contributions of the Irish PADDINGToN Parent Advisory Group
Introduction: Patient and public involvement (PPI) is increasingly recognised as integral to high‐quality neonatal research, yet practical guidance on its implementation remains limited. Purpose: The primary aim of this paper is to describe the establishment and operation of a Parent Advisory Group (PAG) embedded within a national neonatal medicines feasibility study, including facilitators and barriers for ongoing PPI involvement in research. The second aim is to describe how the group's involvement informed study design, recruitment and retention strategies to optimise the research study. Methods: A qualitative descriptive study was undertaken and reported in accordance with the GRIPP2 checklist. Parents with recent neonatal unit experience were recruited through national neonatal networks and institutional PPI platforms. Feedback from meeting transcripts, reflective notes and questionnaires was analysed using an inductive descriptive thematic approach. Results: Seven parents contributed to study materials, recruitment strategies and interpretation of findings through group meetings and asynchronous feedback. Flexible engagement approaches supported participation, although sustaining involvement over time and managing the emotional impact of participation presented challenges. Conclusion: Structured and flexible models of engagement, paired with appropriate supports, can support meaningful parental involvement in neonatal research. This study highlights how parental involvement can inform study design, recruitment and retention planning, and strategies for sustaining parent engagement.
- 9 September 2026
- Published by Wiley in Child: Care, Health and Development
- Vol. 52 (5) , e70334
Open AccessParent Partnership in Neonatal Research: Facilitators, Barriers and Contributions of the Irish PADDINGToN Parent Advisory Group
Introduction: Patient and public involvement (PPI) is increasingly recognised as integral to high‐quality neonatal research, yet practical guidance on its implementation remains limited. Purpose: The primary aim of this paper is to describe the establishment and operation of a Parent Advisory Group (PAG) embedded within a national neonatal medicines feasibility study, including facilitators and barriers for ongoing PPI involvement in research. The second aim is to describe how the group's involvement informed study design, recruitment and retention strategies to optimise the research study. Methods: A qualitative descriptive study was undertaken and reported in accordance with the GRIPP2 checklist. Parents with recent neonatal unit experience were recruited through national neonatal networks and institutional PPI platforms. Feedback from meeting transcripts, reflective notes and questionnaires was analysed using an inductive descriptive thematic approach. Results: Seven parents contributed to study materials, recruitment strategies and interpretation of findings through group meetings and asynchronous feedback. Flexible engagement approaches supported participation, although sustaining involvement over time and managing the emotional impact of participation presented challenges. Conclusion: Structured and flexible models of engagement, paired with appropriate supports, can support meaningful parental involvement in neonatal research. This study highlights how parental involvement can inform study design, recruitment and retention planning, and strategies for sustaining parent engagement.
- Open Access
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
One Ink for Two Processes: Exploiting Rheology to Accelerate 3D-Printed Chewable Tablet Manufacturing
Personalised medicines are increasingly required in paediatric and hospital pharmacy practice, where licensed preparations may not be suitable. Semi-solid extrusion three-dimensional printing (SSE-3DP) enables the production of these patient-specific dosage forms, especially in chewable tablets. However, its layer-by-layer fabrication may limit manufacturing speed and routine implementation in time-pressured hospital pharmacy workflows. This study manufactured theophylline-loaded chewable gummy tablets via two routes: conventional SSE-3DP and template-based ink deposition (TID), using an identical printer and without the need for pharmaceutical ink reformulation. The ink was printed directly at a low temperature to produce cylindrical 3DP tablets, whereas TID extruded at a higher temperature into customised pyramidal template cavities. Rheological assessment of the ink under two processing conditions showed that temperature-dependent viscosity behaviour underpinned the distinct manufacturing routes. Following process optimisation, TID produced gummy tablets in 2-6 sec/unit, a 7-fold increase in process speed compared to 3DP (14-42 sec/unit). TID tablets met the pharmacopoeia requirements for weight and content uniformity, showed overall quality attributes comparable to those of 3DP, and remained stable for up to 28 days at 5°C and 25°C. However, the differing thermal and solidification rates of the two routes resulted in distinct drug-release profiles. Overall, this work extends the functionality of the 3D printer and demonstrates a practical strategy for converting the SSE-3DP process into a rapid dispensing workflow for small-batch personalised gummy medicines in hospital pharmacies and point-of-care settings.
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOne Ink for Two Processes: Exploiting Rheology to Accelerate 3D-Printed Chewable Tablet Manufacturing
Personalised medicines are increasingly required in paediatric and hospital pharmacy practice, where licensed preparations may not be suitable. Semi-solid extrusion three-dimensional printing (SSE-3DP) enables the production of these patient-specific dosage forms, especially in chewable tablets. However, its layer-by-layer fabrication may limit manufacturing speed and routine implementation in time-pressured hospital pharmacy workflows. This study manufactured theophylline-loaded chewable gummy tablets via two routes: conventional SSE-3DP and template-based ink deposition (TID), using an identical printer and without the need for pharmaceutical ink reformulation. The ink was printed directly at a low temperature to produce cylindrical 3DP tablets, whereas TID extruded at a higher temperature into customised pyramidal template cavities. Rheological assessment of the ink under two processing conditions showed that temperature-dependent viscosity behaviour underpinned the distinct manufacturing routes. Following process optimisation, TID produced gummy tablets in 2-6 sec/unit, a 7-fold increase in process speed compared to 3DP (14-42 sec/unit). TID tablets met the pharmacopoeia requirements for weight and content uniformity, showed overall quality attributes comparable to those of 3DP, and remained stable for up to 28 days at 5°C and 25°C. However, the differing thermal and solidification rates of the two routes resulted in distinct drug-release profiles. Overall, this work extends the functionality of the 3D printer and demonstrates a practical strategy for converting the SSE-3DP process into a rapid dispensing workflow for small-batch personalised gummy medicines in hospital pharmacies and point-of-care settings.
- Open Access
- 13 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126871
Accurate low-temperature direct granule extrusion 3D printing of personalised paediatric minitablets
- 13 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126871
Open AccessAccurate low-temperature direct granule extrusion 3D printing of personalised paediatric minitablets
- Open Access
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Accurate Low-Temperature Direct Extrusion 3D Printing of Personalised Paediatric Minitablets
Medicine individualisation remains constrained by the limited availability of age-appropriate strengths and by extemporaneous practices that can compromise dose consistency. Direct powder extrusion (DPE) 3D printing offers an alternative manufacturing method for personalised medicine, without introducing solvents, complex preparation, or post-processing that challenge pharmacy adoption. However, achieving uniform weight and drug content for small objects (e.g., paediatric-friendly minitablets) and lowering the preparation temperature remain challenges for extrusion-based 3D printing technologies.In this work, we introduce a facile low-temperature DPE 3D printing strategy to manufacture carvedilol minitablets, starting from carvedilol powder or licensed tablets as starting materials, using a high-precision pharmaceutical-grade 3D printer. Methacrylate-based polymers, polyethylene glycol, and glyceryl monostearate were used to enable extrusion at 70-75°C. When the 3D printer was challenged with minute-dimensional designs, it was possible to manufacture batches of minitablets up to 2 mm in diameter with 0.8 mm in thickness. The lowest minitablet weight variation was 1.48%, achieved with an optimal diameter of 3.6 mm and a thickness of 1.6 mm; this was also reflected in the drug content uniformity (within ±5%). The immediate-release batch met British Pharmacopoeia requirements (>80% in 45 min), whereas the extended-release formulations exhibited prolonged drug release (>50% in 24 h).These findings extend DPE 3D printing to a viable manufacturing platform for accurate, low-dose small solid units, such as minitablets. By coupling a GMP-compliant 3D printer with a simplified preparation workflow, this work provides a realistic blueprint for integrating DPE-enabled personalised minitablets into hospital pharmacy and point-of-care settings.
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAccurate Low-Temperature Direct Extrusion 3D Printing of Personalised Paediatric Minitablets
Medicine individualisation remains constrained by the limited availability of age-appropriate strengths and by extemporaneous practices that can compromise dose consistency. Direct powder extrusion (DPE) 3D printing offers an alternative manufacturing method for personalised medicine, without introducing solvents, complex preparation, or post-processing that challenge pharmacy adoption. However, achieving uniform weight and drug content for small objects (e.g., paediatric-friendly minitablets) and lowering the preparation temperature remain challenges for extrusion-based 3D printing technologies.In this work, we introduce a facile low-temperature DPE 3D printing strategy to manufacture carvedilol minitablets, starting from carvedilol powder or licensed tablets as starting materials, using a high-precision pharmaceutical-grade 3D printer. Methacrylate-based polymers, polyethylene glycol, and glyceryl monostearate were used to enable extrusion at 70-75°C. When the 3D printer was challenged with minute-dimensional designs, it was possible to manufacture batches of minitablets up to 2 mm in diameter with 0.8 mm in thickness. The lowest minitablet weight variation was 1.48%, achieved with an optimal diameter of 3.6 mm and a thickness of 1.6 mm; this was also reflected in the drug content uniformity (within ±5%). The immediate-release batch met British Pharmacopoeia requirements (>80% in 45 min), whereas the extended-release formulations exhibited prolonged drug release (>50% in 24 h).These findings extend DPE 3D printing to a viable manufacturing platform for accurate, low-dose small solid units, such as minitablets. By coupling a GMP-compliant 3D printer with a simplified preparation workflow, this work provides a realistic blueprint for integrating DPE-enabled personalised minitablets into hospital pharmacy and point-of-care settings.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1702183
Acceptability of minitablets in soft food. A randomised cross-over study in children
Objective: To evaluate the acceptability of placebo minitablets mixed with different volumes of soft food in children aged 6 months to 7 years. Methods: In this UK hospital-based, randomised cross-over study, children received placebo minitablets in yoghurt or apple sauce. Those under 1 year received one sample; older children received two. All participants were video recorded taking the samples. Minitablet counts (50–135), and soft food volumes (7.5–30 mL) increased with age. Children aged 1 year + were randomised to “high” or “low” soft food volumes for the first sample; parents chose the soft-food amount for younger children. Swallowability was rated (1–5) by researchers, and palatability by independent reviewers (‘pleasant’, ‘neutral’, or ‘unpleasant’). Palatability and swallowability scores were then combined to assess overall acceptability using the composite endpoint tool. Children aged 4–7 years completed a participant questionnaire. Results: 100 children were grouped by age: <2 years (G1, n = 16), 2–4 years (G2, n = 37), and ≥5 years (G3, n = 47). Mean age was 4.2 years; 56% were male; 84% were tablet naïve. Youngest was 9 months old. Yoghurt was preferred by 84%. Swallowability was 77% overall, increasing with age (G1: 69%, G2: 73%, G3: 83%). G3 participants consumed more per sample than G1 (at least 80% of minitablets consumed for Samples 1/2, respectively: G3-89%/91% vs. G1-69%/62%). ‘Pleasant’ was the most common palatability rating (48% Sample 1, 52% Sample 2). Some older children reported finding the number of minitablets excessive. Acceptability was 46% (G1), 58% (G2), and 53% (G3), with overall acceptability rated as “high/good” for 54% of participants. Conclusion: Minitablets in soft food were generally acceptable for children aged 9 months to 7 years, especially those aged 2–4 years. Swallowability and palatability were good across all age groups. Larger soft-food volumes were often preferred, but both volumes were well tolerated.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1702183
Open AccessAcceptability of minitablets in soft food. A randomised cross-over study in children
Objective: To evaluate the acceptability of placebo minitablets mixed with different volumes of soft food in children aged 6 months to 7 years. Methods: In this UK hospital-based, randomised cross-over study, children received placebo minitablets in yoghurt or apple sauce. Those under 1 year received one sample; older children received two. All participants were video recorded taking the samples. Minitablet counts (50–135), and soft food volumes (7.5–30 mL) increased with age. Children aged 1 year + were randomised to “high” or “low” soft food volumes for the first sample; parents chose the soft-food amount for younger children. Swallowability was rated (1–5) by researchers, and palatability by independent reviewers (‘pleasant’, ‘neutral’, or ‘unpleasant’). Palatability and swallowability scores were then combined to assess overall acceptability using the composite endpoint tool. Children aged 4–7 years completed a participant questionnaire. Results: 100 children were grouped by age: <2 years (G1, n = 16), 2–4 years (G2, n = 37), and ≥5 years (G3, n = 47). Mean age was 4.2 years; 56% were male; 84% were tablet naïve. Youngest was 9 months old. Yoghurt was preferred by 84%. Swallowability was 77% overall, increasing with age (G1: 69%, G2: 73%, G3: 83%). G3 participants consumed more per sample than G1 (at least 80% of minitablets consumed for Samples 1/2, respectively: G3-89%/91% vs. G1-69%/62%). ‘Pleasant’ was the most common palatability rating (48% Sample 1, 52% Sample 2). Some older children reported finding the number of minitablets excessive. Acceptability was 46% (G1), 58% (G2), and 53% (G3), with overall acceptability rated as “high/good” for 54% of participants. Conclusion: Minitablets in soft food were generally acceptable for children aged 9 months to 7 years, especially those aged 2–4 years. Swallowability and palatability were good across all age groups. Larger soft-food volumes were often preferred, but both volumes were well tolerated.
- 24 November 2025
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (3) , 251-257
Perspectives of stakeholders on running ‘Pill School’ in community settings: a survey based study
Objectives: Liquid formulations are the most widely used pharmaceutical forms among children but may not be the most appropriate. ‘Pill School’ methodologies exist to teach children how to swallow tablets but are not yet integrated into primary care. The aim of this study was to explore the perspectives of key stakeholders on running ‘Pill Schools’. Methods: We used tailored surveys to gather perspectives from four key stakeholder groups: children and young people (CYP); parents and carers; school staff; and healthcare professionals (HCPs) working in general practice. Key findings: In total, 140 people participated, including 11 CYP, 22 parents, 16 school-based staff (50%, n = 8 were head teachers), 91 primary care-based HCPs most of whom were GPs (60.4%, n = 55), pharmacists (16.5%, n = 15), and nurses (10%, n = 9). Most stakeholders consulted were supportive of the concept of ‘Pill School’. Common enablers mentioned by HCPs were time and funding. The main barriers mentioned were time, capacity and workload with others citing parental concerns in addition. Conclusions: The consultation explored stakeholders’ perspectives of teaching children to swallow tablets in community settings. Most stakeholders were supportive of the concept of ‘Pill School’. HCPs favoured starting with children aged 4 and above whilst parents and school staff favoured starting with children from 8 years and above. There was a clear interest in taking this forward to equip children with this life skill early on, avoiding them becoming adults who have difficulty swallowing tablets.
- 24 November 2025
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (3) , 251-257
Perspectives of stakeholders on running ‘Pill School’ in community settings: a survey based study
Objectives: Liquid formulations are the most widely used pharmaceutical forms among children but may not be the most appropriate. ‘Pill School’ methodologies exist to teach children how to swallow tablets but are not yet integrated into primary care. The aim of this study was to explore the perspectives of key stakeholders on running ‘Pill Schools’. Methods: We used tailored surveys to gather perspectives from four key stakeholder groups: children and young people (CYP); parents and carers; school staff; and healthcare professionals (HCPs) working in general practice. Key findings: In total, 140 people participated, including 11 CYP, 22 parents, 16 school-based staff (50%, n = 8 were head teachers), 91 primary care-based HCPs most of whom were GPs (60.4%, n = 55), pharmacists (16.5%, n = 15), and nurses (10%, n = 9). Most stakeholders consulted were supportive of the concept of ‘Pill School’. Common enablers mentioned by HCPs were time and funding. The main barriers mentioned were time, capacity and workload with others citing parental concerns in addition. Conclusions: The consultation explored stakeholders’ perspectives of teaching children to swallow tablets in community settings. Most stakeholders were supportive of the concept of ‘Pill School’. HCPs favoured starting with children aged 4 and above whilst parents and school staff favoured starting with children from 8 years and above. There was a clear interest in taking this forward to equip children with this life skill early on, avoiding them becoming adults who have difficulty swallowing tablets.
- Open Access
- 24 October 2024
- Published by Springer Nature
Analysing the use of glycopyrronium bromide for excessive drooling in young children
- 24 October 2024
- Published by Springer Nature
Open AccessAnalysing the use of glycopyrronium bromide for excessive drooling in young children